# The FDA Advisory Committee on Compounding

Canonical source: https://retacompare.com/research/fda-advisory-committee-compounding-75

FDA · 2026-03-13


    The Pharmacy Compounding Advisory Committee (PCAC) advises FDA on matters related to compounded drug products, including nominations for the 503A bulks list and related policy questions. The committee held meetings in November 2025 and March 2026 that addressed the GLP-1 agonist peptides. In both meetings PCAC declined to recommend addition of tirzepatide, semaglutide, or retatrutide to the bulks list, citing safety concerns, the availability of FDA-approved alternatives for tirzepatide and semaglutide, and the investigational status of retatrutide. The advisory committee record provides substantial detail on FDA's technical reasoning.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources